Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07465302 · ClinicalTrials.gov registry record · Phase 2

Treating Spinal Cord Injury With Early Normobaric Hyperoxia

A Phase 2 study, sponsored by University of Florida.

Recruiting
Registry status
Phase 2
Development phase
12
Enrollment target

NCT07465302: Recruiting Phase 2 study, sponsored by University of Florida.

NCT07465302 is a Phase 2 study that is actively recruiting participants, run by University of Florida. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07465302, a Phase 2 study, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

SpiCoH is a phase IIa, single center, open-label, clinical trial of intermittent normobaric hyperoxia in mechanically ventilated patients with traumatic cervical and/or thoracic spinal cord injury.

Primary Outcome

Proportion of subjects receiving first normobaric hyperoxia therapy.

Interventions

  • OTHER Normobaric Hyperoxia

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-04-15
Est. Completion 2028-09-30
Phase Phase 2
University of Florida

1,106 total trials

What NCT07465302 shows while recruiting

NCT07465302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Normobaric Hyperoxia is the first listed.

NCT07465302 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07465302 about?

NCT07465302 is a clinical study titled "Treating Spinal Cord Injury With Early Normobaric Hyperoxia". SpiCoH is a phase IIa, single center, open-label, clinical trial of intermittent normobaric hyperoxia in mechanically ventilated patients with traumatic cervical and/or thoracic spinal cord injury.

What is the current status of trial NCT07465302?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2026-04-15. Estimated completion is 2028-09-30.

What interventions are being tested in trial NCT07465302?

The interventions under investigation include: Normobaric Hyperoxia (OTHER).

Who is sponsoring clinical trial NCT07465302?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07465302's enrollment target sits among peer trials

12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07465302, the US trial registry maintained by the National Library of Medicine. NCT07465302 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.